Arthneeti
All Q2 FY27 results →
B

Biocon Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Biocon Q2 Results 2026 (FY27): Revenue ₹4,389 Cr, PAT ₹44 Cr

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹343
Market cap₹55.9K Cr
P/E76.9
Updated4 Nov 2026
Read3 min read

Biocon Ltd Q2 FY27 key numbers

Revenue
Q2 FY27 Revenue from Operations: ₹4,389 Cr, up 2% YoY.

As stated in Biocon Ltd's Q2 FY27 investor presentation · published 4 Nov 2026. Reported figures, not investment advice.

Based on Biocon Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY27 Revenue from Operations: ₹4,389 Cr, up 2% YoY. Q2 FY27 EBITDA: ₹865 Cr, down 7% YoY; EBITDA margin: 20% (Q2 FY26: 22%) [Page 8].

From Biocon Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.

How did Biocon's revenue grow in the September 2026 quarter?

- Q2 FY27 Revenue from Operations: ₹4,389 Cr, up 2% YoY - Biopharmaceuticals Revenue: ₹3,583 Cr, up 5% YoY - Biosimilars: ₹2,809 Cr, up 3% YoY - Generics: ₹774 Cr, up 10% YoY - Services Revenue: ₹833 Cr, down 9% YoY - H1 FY27 Revenue from Operations: ₹8,725 Cr, up 6% YoY - Biosimilars H1 FY27 Revenue: ₹5,664 Cr, up 9% YoY - Generics H1 FY27 Revenue: ₹1,536 Cr, up 15% YoY - Services H1 FY27 Revenue: ₹1,569 Cr, down 12% YoY **Outlook:** - Stronger H2 FY27 expected with momentum from Biosimilars launches and enhanced insulin capacity

2 more points from Biocon Ltd's call on revenue

Create a free account to keep reading this call

What happened to Biocon's margins in Q2 FY27?

See what Biocon Ltd said on profitability & margins — free account, 30 seconds.

What capex is Biocon planning?

  • Additional insulin fill-finish capacity commissioned in Malaysia, supporting strong insulin demand (Page 11).
  • Launch momentum and enhanced insulins capacity expected to support a stronger H2 FY27 (Pages 11, 17).
  • Pertuzumab 10-year partnership in Brazil secured with US$400 million TCV, strengthening long-term revenue visibility (Page 11, 6).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Biocon raising money or cutting debt?

See what Biocon Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Biocon's order book?

Key relevant points from the presentation include: - References to business momentum and growth outlook, such as: - Biosimilars launch momentum and enhanced insulin capacity supporting stronger H2 (Page 17). - 10-year Brazil Pertuzumab partnership with US$400 million total contract value, indicating long-term revenue visibility (Page 11).

2 more points from Biocon Ltd's call on order book

Create a free account to keep reading this call

Biocon Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Biocon Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Alembic Pharma (Q2 FY27)

    Total Revenue for Q2 FY27: ₹26.03 billion, up 36% YoY (Page 12, Page 4) . Key investor presentation takeaways from Alembic Pharmaceuticals Ltd's Q2 FY27 investo

  • Marksans Pharma Ltd (Q2 FY27)

    Q2FY27 Total Income: ₹958.3 crore (29.2% YoY growth) . Key investor presentation takeaways from Marksans Pharma Ltd's Q2 FY27 investor presentation — and how it

  • Zydus Lifesciences (Q2 FY27)

    79,096 mn, up 29.2% YoY (Page 14) . Key investor presentation takeaways from Zydus Lifesciences Ltd's Q2 FY27 investor presentation — and how it ranks against s

  • Lupin (Q2 FY27)

    Q2 FY27 Net Sales: ₹77,855 million, up 14.0% YoY (Page 13) . Key investor presentation takeaways from Lupin Ltd's Q2 FY27 investor presentation — and how it ran

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Biocon Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Biocon Ltd Q2 FY27 results?

Q2 FY27 Revenue from Operations: ₹4,389 Cr, up 2% YoY. Q2 FY27 EBITDA: ₹865 Cr, down 7% YoY; EBITDA margin: 20% (Q2 FY26: 22%) [Page 8].

What is Biocon Ltd share price analysis?

Biocon Ltd currently shows a neutral. The stock trades at a P/E of 76.9 with a market cap of ₹55,931 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon Ltd planning capital expenditure?

Additional insulin fill-finish capacity commissioned in Malaysia, supporting strong insulin demand (Page 11).

Keep Biocon Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.